Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Industrifonden (1)
Mandate

Vinge advises Industrifonden

January 19, 2009

Vinge has advised the Foundation, Industrifonden in connection with the sale of its holding in Stockholm International Jazz & Blues Festival AB to Jensen Invest AB. Industrifonden and the Swedish Artists and Musicians Interest Organisation have jointly run the annual jazz festival at Skeppsholmen since 2003.
 
Jensen Invest with its owner, Ingvar Jensen, former majority owner of the electronics company, ELFA, has supported and developed cultural activities and non-profit making associations for many years and is currently planning this year’s festival which is due to take place at Skeppsholmen on 16-18 July. The new board of directors consists of Christina Jutterström (Chairwoman), Ingvar Jensen, Sven-Åke Johansson and Lena Åberg Frisk.
 
Mi Gustafsson advised Industrifonden. The responsible partner is Johan Winnerblad.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024